JP2008523082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523082A5 JP2008523082A5 JP2007545627A JP2007545627A JP2008523082A5 JP 2008523082 A5 JP2008523082 A5 JP 2008523082A5 JP 2007545627 A JP2007545627 A JP 2007545627A JP 2007545627 A JP2007545627 A JP 2007545627A JP 2008523082 A5 JP2008523082 A5 JP 2008523082A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- hydroxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 91
- 229910052739 hydrogen Inorganic materials 0.000 claims 79
- 239000001257 hydrogen Substances 0.000 claims 79
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 71
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 38
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 37
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 35
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 35
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims 34
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims 32
- 125000001475 halogen functional group Chemical group 0.000 claims 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 31
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 30
- 125000004423 acyloxy group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 24
- -1 oxy, thio Chemical group 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 241001465754 Metazoa Species 0.000 claims 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 14
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 150000001540 azides Chemical class 0.000 claims 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 10
- 229930024421 Adenine Natural products 0.000 claims 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 7
- 229960000643 adenine Drugs 0.000 claims 7
- 229940104302 cytosine Drugs 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229940113082 thymine Drugs 0.000 claims 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 7
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940035893 uracil Drugs 0.000 claims 6
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- KIMCWRBPIXPGPA-LLVKDONJSA-N [[(2r)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]amino]phosphonic acid Chemical compound C1=CC=C2C(C[C@H](C(=O)NC)NP(O)(O)=O)=CNC2=C1 KIMCWRBPIXPGPA-LLVKDONJSA-N 0.000 claims 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 235000013928 guanylic acid Nutrition 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000006301 indolyl methyl group Chemical group 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000005289 uranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63467704P | 2004-12-09 | 2004-12-09 | |
| PCT/US2005/044442 WO2006063149A1 (en) | 2004-12-09 | 2005-12-08 | Nucleosides with antiviral and anticancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523082A JP2008523082A (ja) | 2008-07-03 |
| JP2008523082A5 true JP2008523082A5 (enExample) | 2009-01-22 |
Family
ID=36578243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545627A Withdrawn JP2008523082A (ja) | 2004-12-09 | 2005-12-08 | 抗菌活性および抗癌活性を有するヌクレオチド |
Country Status (5)
| Country | Link |
|---|---|
| US (7) | US8399428B2 (enExample) |
| EP (1) | EP1827460A4 (enExample) |
| JP (1) | JP2008523082A (enExample) |
| CA (1) | CA2589935A1 (enExample) |
| WO (1) | WO2006063149A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1827460A4 (en) | 2004-12-09 | 2012-03-14 | Univ Minnesota | NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT |
| WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| JP2010513484A (ja) * | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| EP2144921A2 (en) * | 2007-02-27 | 2010-01-20 | K.U. Leuven Research and Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
| US8716263B2 (en) * | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| EA026341B9 (ru) | 2010-03-31 | 2021-12-27 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Кристаллическая форма нуклеозидфосфорамидата |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| CA2828326C (en) | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2734535A4 (en) * | 2011-07-19 | 2014-10-22 | Nanjing Molecular Res Inc | 2 ', 3'-DIDEOXY-2'-ALPHA-FLUOR-2'-BETA-C-METHYL NUCLEOSIDE AND PRODRUGS THEREOF |
| TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| CN104470939B (zh) | 2012-05-22 | 2017-04-26 | 埃迪尼克斯医药有限责任公司 | 用于肝脏疾病的d型氨基酸化合物 |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| HK1207647A1 (en) | 2012-10-08 | 2016-02-05 | Idenix Pharmaceuticals Llc | 2'-chloro nucleoside analogs for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) * | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| HRP20191461T1 (hr) * | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| EP3233878B1 (en) | 2014-12-15 | 2025-09-03 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| HK1252245A1 (zh) * | 2015-05-27 | 2019-05-24 | Idenix Pharmaceuticals Llc | 用於治疗癌症的核苷酸 |
| EP3344642A1 (en) | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Anti-viral tetrahydrofurane derivatives |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| EA201990059A1 (ru) | 2016-06-24 | 2019-07-31 | Эмори Юниверсити | Фосфорамидаты для лечения вируса гепатита b |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2019201283A1 (en) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| US11439656B2 (en) * | 2018-08-30 | 2022-09-13 | Regents Of The University Of Minnesota | Pharmaceutical compounds and uses thereof |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827337D0 (en) | 1988-11-23 | 1988-12-29 | Medical Res Council | Nucleoside analogues |
| US5614504A (en) | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| GB9207381D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
| US5696097A (en) | 1993-03-18 | 1997-12-09 | Yamasa Corporation | Antineoplastic 5'-diacylglycerylphosphatidyl-2-deoxy-2'-methylenylcytidines and method of making |
| US6677310B1 (en) | 1999-04-21 | 2004-01-13 | Nabi | Ring-expanded nucleosides and nucleotides |
| US5475985A (en) * | 1993-12-14 | 1995-12-19 | Carrier Corporation | Electronic control of liquid cooled compressor motors |
| US5659023A (en) | 1995-02-01 | 1997-08-19 | Gilead Sciences, Inc. | Nucleotide analogues |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| US5981507A (en) | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
| US6475985B1 (en) * | 1998-03-27 | 2002-11-05 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| US6030957A (en) * | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| MXPA02000763A (es) * | 1999-07-22 | 2002-08-12 | Newbiotics Inc | Activacion terapeutica catalizada por enzima. |
| WO2001074827A1 (en) * | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Phosphoramidate prodrugs |
| WO2003000713A1 (en) * | 2001-06-21 | 2003-01-03 | Glaxo Group Limited | Nucleoside compounds in hcv |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| KR100883703B1 (ko) | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | 변형 불소화 뉴클레오시드 유사체 |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| US20070265222A1 (en) | 2004-06-24 | 2007-11-15 | Maccoss Malcolm | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection |
| WO2006065335A2 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| EP1827460A4 (en) | 2004-12-09 | 2012-03-14 | Univ Minnesota | NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT |
| US7964582B2 (en) | 2005-03-21 | 2011-06-21 | J&J Consumer Companies, Inc. | Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
-
2005
- 2005-12-08 EP EP05853381A patent/EP1827460A4/en not_active Withdrawn
- 2005-12-08 WO PCT/US2005/044442 patent/WO2006063149A1/en not_active Ceased
- 2005-12-08 JP JP2007545627A patent/JP2008523082A/ja not_active Withdrawn
- 2005-12-08 CA CA002589935A patent/CA2589935A1/en not_active Abandoned
- 2005-12-08 US US11/721,325 patent/US8399428B2/en not_active Expired - Fee Related
-
2013
- 2013-01-29 US US13/753,252 patent/US8765935B2/en not_active Expired - Lifetime
-
2014
- 2014-03-28 US US14/229,292 patent/US8815830B2/en not_active Expired - Lifetime
- 2014-07-21 US US14/336,225 patent/US20150025220A1/en not_active Abandoned
-
2016
- 2016-02-16 US US15/044,853 patent/US20160159845A1/en not_active Abandoned
-
2017
- 2017-10-18 US US15/787,140 patent/US20180258131A1/en not_active Abandoned
-
2019
- 2019-02-27 US US16/287,387 patent/US20200095273A1/en not_active Abandoned